Attorney Docket No.: Client Ref.:	RSW86283US P17733 DrB/bin
Applicant: PCT App. No.: Serial No.: Filing/371 Date: For: Group: Examiner: Confirmation No.	Kirschning et al. PCT/EP2004/010700 10/595,204 Mar. 23, 2006 TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF TBD TBD TBD 4608
1	POWER OF ATTORNEY BY ASSIGNEE, CHANGE OF CORRESPONDENCE ADDRESS EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71 AND STATEMENT UNDER 37 C.F.R. 3.73(b)
Dear Sir:	
Amgen Inc. states it is an assignce of a 50% interest in the above-identified subject application by virtue of one or more assignments:	
[X]	that was recorded on <u>2/28/07</u> at reel/frame <u>018940/0072</u> .
C _p I	that is submitted herewith for recording.
[]	for which a copy thereof is attached.
Amgen Inc. hereby appoints the practitioners associated with Customer Number 65159 and David W. Maher, Reg. No. 40,077 as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.	
Please direct Customer Number 651:	all correspondence relative to this application to the address associated with 59 and direct all telephone calls to David W. Maher at (858) 228-7829.
I am authorized to act on behalf of Amgen Inc.	
Signature: Typed/Printed Name:	Stuart I Watt by Her
Title:	Vice President, LAW
Date:	October 1, 2007